Skip to main content

Table 3 Univariate and multivariate analyses for progression-free survival (PFS)

From: Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients

Variable Univariate Multivariate
HR (95%CI) P value HR (95%CI) P value
Age, years   0.138   0.008
  ≤ 50 1.0   1.0  
 >50 0.75 (0.51–1.10)   0.69 (0.52–0.91)  
Gender   0.780   
 Female 1.0    
 Male 1.09 (0.59–2.04)    
Vascular invasion   0.025   < 0.001
 No 1.0   1.0  
 Yes 1.57 (1.06–2.33)   2.19 (1.42–3.36)  
Extrahepatic metastasis   0.001   0.014
 No 1.0   1.0  
 Yes 1.97 (1.34–2.91)   1.67 (1.11–2.49)  
ALBI grade   < 0.001   <0.001
 I 1.0   1.0  
 II 2.13 (1.45–3.13)   2.04 (1.39–3.00)  
AFP reduction> 50%   <0.001   <0.001
 No 1.0   1.0  
 Yes 0.37 (0.25–0.56)   0.38 (0.23–0.61)  
PIVKA-II reduction> 50%   0.001   0.021
 No 1.0   1.0  
 Yes 0.46 (0.31–0.68)   0.60 (0.39–0.93)  
Baseline AFP level > 400 ng/ml   < 0.001   0.001
 No 1.0   1.0  
 Yes 2.37 (1.49–3.77)   2.25 (1.41–3.59)  
Baseline PIVKA-II level > 400 mAU/ml   0.164   
 No 1.0    
 Yes 1.47 (0.85–2.55)